-Advertisement-
-Advertisement-
Conference Roundup
Pulmonary and Lung

New Opsumit (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with Pulmonary Arterial Hypertension

Posted on May 31, 2020
New Opsumit (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with Pulmonary Arterial Hypertension

Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announces new data evaluating initial combination therapy with Opsumit (macitentan) and tadalafIl, a PDE5 inhibitor. Patients with pulmonary arterial hypertension (PAH, WHO Group 1) taking this combination showed hemodynamic improvement, as well as improvements in functional parameters and risk profiles. The combination was also well tolerated in these patients. The study data is being shared today at the CHEST Annual Meeting 2019, held October 19-23 in New Orleans, Louisiana.

The OPTIMA (cOmbination theraPy of maciTentan and tadalafIl in patients with newly diagnosed pulMonary Arterial Hypertension) study was a prospective, multicenter, single-arm, open-label, Phase IV trial evaluating the efficacy, safety, and tolerability of initial oral combination therapy with OPSUMIT and tadalafil in patients with newly diagnosed PAH. A total of 46 patients were enrolled in the study.

Read the full press release here.

Source: Actelion Pharmaceuticals Ltd
-Advertisement-
Related Articles
FDA Approves First Treatment for Chronic Fibrosing ILDs with Progressive Phenotype
Mar 16, 2020
AAAI Cancels Annual Meeting
Mar 14, 2020
Inhaled Nitric Oxide Improves Physical Activity Iin Patients with Pulmonary Fibrosis At-risk for Pulmonary Hypertension
Mar 11, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-